RU2013142437A - Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных - Google Patents
Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных Download PDFInfo
- Publication number
- RU2013142437A RU2013142437A RU2013142437/15A RU2013142437A RU2013142437A RU 2013142437 A RU2013142437 A RU 2013142437A RU 2013142437/15 A RU2013142437/15 A RU 2013142437/15A RU 2013142437 A RU2013142437 A RU 2013142437A RU 2013142437 A RU2013142437 A RU 2013142437A
- Authority
- RU
- Russia
- Prior art keywords
- animal
- damage
- nervous system
- ufa
- component
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 142
- 241001465754 Metazoa Species 0.000 title claims abstract 123
- 230000006378 damage Effects 0.000 title claims abstract 108
- 239000000203 mixture Substances 0.000 title claims 27
- 230000002265 prevention Effects 0.000 title claims 3
- 230000009467 reduction Effects 0.000 title claims 2
- 210000000653 nervous system Anatomy 0.000 claims abstract 49
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract 45
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract 45
- 210000004498 neuroglial cell Anatomy 0.000 claims abstract 21
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract 16
- 210000004027 cell Anatomy 0.000 claims abstract 12
- 210000002569 neuron Anatomy 0.000 claims abstract 10
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract 8
- 208000003098 Ganglion Cysts Diseases 0.000 claims abstract 7
- 102000006386 Myelin Proteins Human genes 0.000 claims abstract 7
- 108010083674 Myelin Proteins Proteins 0.000 claims abstract 7
- 208000005400 Synovial Cyst Diseases 0.000 claims abstract 7
- 210000005012 myelin Anatomy 0.000 claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 210000004116 schwann cell Anatomy 0.000 claims abstract 5
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims abstract 5
- 210000003050 axon Anatomy 0.000 claims abstract 3
- 210000004556 brain Anatomy 0.000 claims abstract 3
- 210000005056 cell body Anatomy 0.000 claims abstract 3
- 210000001787 dendrite Anatomy 0.000 claims abstract 3
- 239000012636 effector Substances 0.000 claims abstract 3
- 208000014674 injury Diseases 0.000 claims abstract 3
- 210000000278 spinal cord Anatomy 0.000 claims abstract 3
- 210000000225 synapse Anatomy 0.000 claims abstract 3
- 210000001130 astrocyte Anatomy 0.000 claims abstract 2
- 210000000274 microglia Anatomy 0.000 claims abstract 2
- 210000004248 oligodendroglia Anatomy 0.000 claims abstract 2
- 239000003963 antioxidant agent Substances 0.000 claims 23
- 235000006708 antioxidants Nutrition 0.000 claims 23
- 235000019156 vitamin B Nutrition 0.000 claims 22
- 239000011720 vitamin B Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 19
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 15
- 239000001961 anticonvulsive agent Substances 0.000 claims 14
- 229960003965 antiepileptics Drugs 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 235000013305 food Nutrition 0.000 claims 9
- 208000028389 Nerve injury Diseases 0.000 claims 8
- 230000032683 aging Effects 0.000 claims 7
- 230000001773 anti-convulsant effect Effects 0.000 claims 7
- 239000000935 antidepressant agent Substances 0.000 claims 7
- 239000003246 corticosteroid Substances 0.000 claims 7
- 239000003018 immunosuppressive agent Substances 0.000 claims 7
- 229940124589 immunosuppressive drug Drugs 0.000 claims 7
- 235000020938 metabolic status Nutrition 0.000 claims 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims 7
- 230000009885 systemic effect Effects 0.000 claims 7
- 239000004475 Arginine Substances 0.000 claims 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 229960003121 arginine Drugs 0.000 claims 6
- 229960002173 citrulline Drugs 0.000 claims 6
- 235000013477 citrulline Nutrition 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 229960003104 ornithine Drugs 0.000 claims 6
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 5
- 102000003951 Erythropoietin Human genes 0.000 claims 5
- 108090000394 Erythropoietin Proteins 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 5
- 108700011259 MicroRNAs Proteins 0.000 claims 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 5
- 239000003557 cannabinoid Substances 0.000 claims 5
- 229930003827 cannabinoid Natural products 0.000 claims 5
- 229940105423 erythropoietin Drugs 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 5
- 229960004194 lidocaine Drugs 0.000 claims 5
- 229960003404 mexiletine Drugs 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- -1 neurotropin Substances 0.000 claims 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 5
- 229930002330 retinoic acid Natural products 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229940084026 sodium valproate Drugs 0.000 claims 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 5
- 229960001727 tretinoin Drugs 0.000 claims 5
- 229960000604 valproic acid Drugs 0.000 claims 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- 208000001738 Nervous System Trauma Diseases 0.000 claims 4
- 239000000654 additive Substances 0.000 claims 4
- 150000001483 arginine derivatives Chemical class 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 3
- 239000002417 nutraceutical Substances 0.000 claims 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 3
- 229930003231 vitamin Natural products 0.000 claims 3
- 235000013343 vitamin Nutrition 0.000 claims 3
- 239000011782 vitamin Substances 0.000 claims 3
- 229940088594 vitamin Drugs 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 2
- 101150036143 NTF3 gene Proteins 0.000 claims 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 229960000623 carbamazepine Drugs 0.000 claims 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 235000019197 fats Nutrition 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 230000033001 locomotion Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 230000007659 motor function Effects 0.000 claims 2
- 229960002036 phenytoin Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 229960001233 pregabalin Drugs 0.000 claims 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000037152 sensory function Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 230000036642 wellbeing Effects 0.000 claims 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 1
- 235000013793 astaxanthin Nutrition 0.000 claims 1
- 239000001168 astaxanthin Substances 0.000 claims 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims 1
- 229940022405 astaxanthin Drugs 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091008690 chemoreceptors Proteins 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108091008699 electroreceptors Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000007166 healthy aging Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 235000012680 lutein Nutrition 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- 229960005375 lutein Drugs 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000412 mechanoreceptor Anatomy 0.000 claims 1
- 108091008704 mechanoreceptors Proteins 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000007383 nerve stimulation Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 229960003753 nitric oxide Drugs 0.000 claims 1
- 210000000929 nociceptor Anatomy 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 238000000053 physical method Methods 0.000 claims 1
- 238000002616 plasmapheresis Methods 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 235000011649 selenium Nutrition 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 229940091258 selenium supplement Drugs 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 210000003051 thermoreceptor Anatomy 0.000 claims 1
- 108091008689 thermoreceptors Proteins 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
- 235000010930 zeaxanthin Nutrition 0.000 claims 1
- 239000001775 zeaxanthin Substances 0.000 claims 1
- 229940043269 zeaxanthin Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Birds (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161463594P | 2011-02-18 | 2011-02-18 | |
| US61/463,594 | 2011-02-18 | ||
| PCT/US2012/024137 WO2012112340A2 (en) | 2011-02-18 | 2012-02-07 | Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013142437A true RU2013142437A (ru) | 2015-03-27 |
Family
ID=46673093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013142437/15A RU2013142437A (ru) | 2011-02-18 | 2012-02-07 | Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130324608A1 (enExample) |
| EP (1) | EP2675447A4 (enExample) |
| JP (1) | JP2014514248A (enExample) |
| CN (1) | CN103764136A (enExample) |
| AU (1) | AU2012218094A1 (enExample) |
| BR (1) | BR112013020802A2 (enExample) |
| CA (1) | CA2827715A1 (enExample) |
| MX (1) | MX2013009544A (enExample) |
| RU (1) | RU2013142437A (enExample) |
| WO (1) | WO2012112340A2 (enExample) |
| ZA (1) | ZA201306990B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014108808A2 (en) * | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| US20150328176A1 (en) * | 2013-01-25 | 2015-11-19 | Winning The Fight Inc. | Composition for treatment of neurodegenerative disease |
| US20160331712A1 (en) * | 2013-12-19 | 2016-11-17 | Tassos Georgiou | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system |
| CN104146253A (zh) * | 2014-08-13 | 2014-11-19 | 胡安然 | 癫痫全营养配方食品 |
| CN110913689A (zh) * | 2017-05-10 | 2020-03-24 | 罗切斯特大学 | 治疗神经精神病症的方法 |
| CN109300527A (zh) * | 2018-12-14 | 2019-02-01 | 苏州大学 | 饮食信息的推荐方法 |
| WO2021247124A1 (en) * | 2020-06-01 | 2021-12-09 | Corona Feed Additives, L.L.C. | Composition, system and method for a pig contraceptive |
| US20230016955A1 (en) * | 2020-06-01 | 2023-01-19 | Corona Feed Additives, L.L.C. | Animal Contraceptive |
| MX2022015535A (es) * | 2020-06-16 | 2023-01-30 | Md Healthcare Inc | Composicion para la prevencion o el tratamiento de trastornos neurologicos o mentales que comprenden vesiculas extraceluares derivadas de lactobacillus paracasei. |
| CN113368171A (zh) * | 2021-06-18 | 2021-09-10 | 长江大学 | 枸杞在预防放射治疗导致的认知功能障碍药物中的应用 |
| CN113322213B (zh) * | 2021-07-09 | 2022-05-13 | 吉林大学 | 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5883087A (en) * | 1991-01-07 | 1999-03-16 | Pherin Corporation | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US5308832A (en) * | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
| WO1998008500A1 (en) * | 1996-08-26 | 1998-03-05 | Board Of Regents, The University Of Texas System | Hypertonic arginine compositions and methods |
| CA2270795A1 (en) * | 1999-05-05 | 2000-11-05 | Gestilab Inc. | Neuroprotective compositions and uses thereof |
| US7135498B1 (en) * | 1999-06-14 | 2006-11-14 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| NZ516513A (en) * | 1999-06-14 | 2004-03-26 | Ford Henry Health System | Nitric oxide donors for inducing neurogenesis |
| US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| US6469049B1 (en) * | 2000-04-21 | 2002-10-22 | The United States Of America As Represented By The Secretary Of The Army | Method of treating, preventing or inhibiting central nervous system injuries and diseases |
| US7563862B2 (en) * | 2001-08-24 | 2009-07-21 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and methods for their use in treatment of brain damage |
| AU2002336638A1 (en) * | 2001-10-12 | 2003-04-28 | Cornell Research Foundation, Inc. | Reversing or preventing premature vascular senescence |
| JP2003261456A (ja) * | 2002-03-08 | 2003-09-16 | Howaizu:Kk | 脳の老化予防剤 |
| US20040186488A1 (en) * | 2003-03-17 | 2004-09-23 | Droese Karl William | Method of peripheral nerve reconstruction using a micro suction connector |
| US6951658B1 (en) * | 2003-07-08 | 2005-10-04 | Pearson Research & Development Limited | Emu-based compositions for mental well-being and method of use |
| CA2598525A1 (en) * | 2005-02-22 | 2006-08-31 | Mochida Pharmaceutical Co., Ltd. | Nerve regeneration promoting agent |
| US20100254951A1 (en) * | 2005-02-22 | 2010-10-07 | Mochida Pharmaceutical Co., Ltd. | Nerve Regeneration Promoting Agent |
| JP2008533005A (ja) * | 2005-03-11 | 2008-08-21 | ヴァーダ コンサルティング リミテッド | 生物学的活性物質の皮内的、経皮的又は経粘膜的送達のための方法 |
| EP1915613A4 (en) * | 2005-07-08 | 2008-11-05 | Philadelphia Health & Educatio | METHOD FOR MONITORING THE NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR THE TREATMENT OF DISEASES COMPRISING A COMPOSITION COMPONENT RELATED TO PHOSPHOLIPASE A2 |
| ES2365628T3 (es) * | 2005-08-26 | 2011-10-07 | Nestec S.A. | Composiciones y métodos para mejorar la integridad vascular funcional, la supervivencia celular y la reducción de la apoptosis después de un episodio isquémico en el cerebro. |
| WO2007022991A1 (en) | 2005-08-26 | 2007-03-01 | Nestec S.A. | Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain |
| WO2007050318A2 (en) * | 2005-10-24 | 2007-05-03 | Duke University | Lipidomics approaches for central nervous system disorders |
| CN101909632A (zh) * | 2008-01-04 | 2010-12-08 | 雀巢产品技术援助有限公司 | 包含不饱和脂肪酸和一氧化氮释放化合物的组合物及其用于增强认知和相关功能的用途 |
| US20090214484A1 (en) * | 2008-02-22 | 2009-08-27 | Nikolay Mironov | Stem cell therapy for the treatment of central nervous system disorders |
-
2012
- 2012-02-07 MX MX2013009544A patent/MX2013009544A/es unknown
- 2012-02-07 AU AU2012218094A patent/AU2012218094A1/en not_active Abandoned
- 2012-02-07 RU RU2013142437/15A patent/RU2013142437A/ru unknown
- 2012-02-07 CA CA2827715A patent/CA2827715A1/en not_active Abandoned
- 2012-02-07 CN CN201280018853.7A patent/CN103764136A/zh active Pending
- 2012-02-07 US US13/985,884 patent/US20130324608A1/en not_active Abandoned
- 2012-02-07 EP EP12747397.3A patent/EP2675447A4/en not_active Withdrawn
- 2012-02-07 WO PCT/US2012/024137 patent/WO2012112340A2/en not_active Ceased
- 2012-02-07 JP JP2013554477A patent/JP2014514248A/ja active Pending
- 2012-02-07 BR BR112013020802A patent/BR112013020802A2/pt not_active IP Right Cessation
-
2013
- 2013-09-17 ZA ZA2013/06990A patent/ZA201306990B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103764136A (zh) | 2014-04-30 |
| JP2014514248A (ja) | 2014-06-19 |
| MX2013009544A (es) | 2013-09-26 |
| EP2675447A4 (en) | 2015-04-22 |
| WO2012112340A2 (en) | 2012-08-23 |
| EP2675447A2 (en) | 2013-12-25 |
| CA2827715A1 (en) | 2012-08-23 |
| BR112013020802A2 (pt) | 2016-10-04 |
| ZA201306990B (en) | 2015-04-29 |
| AU2012218094A1 (en) | 2013-08-29 |
| US20130324608A1 (en) | 2013-12-05 |
| WO2012112340A3 (en) | 2014-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013142437A (ru) | Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных | |
| EP2667882B1 (en) | Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals | |
| RU2010132637A (ru) | Композиции, включающие ненасыщенные жирные кислоты и соединения, высбождающие оксид азота, и их применение для усиления когнитивной функции и связанных с ней функцией | |
| JP6301655B2 (ja) | 健康な皮膚の促進に適した方法及び組成物 | |
| CN101820754A (zh) | 用于增强认知功能的组合物与方法 | |
| JP6820868B2 (ja) | 動物において神経新生を増強するための組成物及び方法 | |
| JP2014515011A (ja) | 加齢に伴う疾病を改善するのに有用な組成物及び方法 | |
| US10668041B2 (en) | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy | |
| AU2015358958B2 (en) | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy | |
| US11284633B2 (en) | Pet food composition for managing non-food allergies | |
| CA2731580A1 (en) | Methods and compositions for preventing, reducing, or treating damage caused by ischemia and ischemia-like conditions |